Exon 14 Deleted MET Receptor as a New Biomarker and Target in Cancers

MET Amplification and Exon 14 Splice Site Mutation Define Unique Molecular Subgroups of Non-Small Cell Lung Carcinoma with Poor Prognosis

(2016) J. H. Tong et al.   CLINICAL CANCER RESEARCH

A never-smoker lung adenocarcinoma patient with a MET exon 14 mutation (D1028N) and a rapid partial response after crizotinib

(2016) Linda Mahjoubi et al.   INVESTIGATIONAL NEW DRUGS

Lazarus-Type Response to Crizotinib in a Patient with Poor Performance Status and Advanced MET Exon 14 Skipping Mutation–Positive Lung Adenocarcinoma

(2016) Meghan Shea et al.   Journal of Thoracic Oncology

Acquired Resistance to Crizotinib in NSCLC with MET  Exon 14 Skipping

(2016) Rebecca S. Heist et al.   Journal of Thoracic Oncology

The Unique Characteristics of MET Exon 14 Mutation in Chinese Patients with NSCLC

(2016) Si-Yang Liu et al.   Journal of Thoracic Oncology

Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations

(2016) Alexa B. Schrock et al.   Journal of Thoracic Oncology

MET Exon 14 Skipping in Non-Small Cell Lung Cancer

(2016) Rebecca S. Heist et al.   ONCOLOGIST

Mutations Preventing Regulated Exon Skipping in MET Cause Osteofibrous Dysplasia

(2015) Mary J. Gray et al.   AMERICAN JOURNAL OF HUMAN GENETICS

c-Myc Alterations Confer Therapeutic Response and Acquired Resistance to c-Met Inhibitors in MET-Addicted Cancers

(2015) Aijun Shen et al.   CANCER RESEARCH

Response to Crizotinib in a Patient With Lung Adenocarcinoma Harboring a MET Splice Site Mutation

(2015) Russell W. Jenkins et al.   Clinical Lung Cancer

Improved diagnostics targeting c-MET in non-small cell lung cancer: expression, amplification and activation?

(2015) I. Watermann et al.   Diagnostic Pathology

MET-Mutated NSCLC with Major Response to Crizotinib

(2015) Melody A. Mendenhall et al.   Journal of Thoracic Oncology

MET Mutation Associated with Responsiveness to Crizotinib

(2015) Saiama N. Waqar et al.   Journal of Thoracic Oncology

Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation

(2015) Susan E. Jorge et al.   LUNG CANCER

MET gene exon 14 deletion created using the CRISPR/Cas9 system enhances cellular growth and sensitivity to a MET inhibitor

(2015) Yosuke Togashi et al.   LUNG CANCER

Inhibition of ABCB1 Overcomes Cancer Stem Cell-like Properties and Acquired Resistance to MET Inhibitors in Non-Small Cell Lung Cancer

(2015) T. Sugano et al.   MOLECULAR CANCER THERAPEUTICS

A novel protein isoform of the RON tyrosine kinase receptor transforms human pancreatic duct epithelial cells

(2015) J Chakedis et al.   ONCOGENE

Response to MET Inhibitors in Patients with Stage IV Lung Adenocarcinomas Harboring MET Mutations Causing Exon 14 Skipping

(2015) P. K. Paik et al.   Cancer Discovery

Activation of MET via Diverse Exon 14 Splicing Alterations Occurs in Multiple Tumor Types and Confers Clinical Sensitivity to MET Inhibitors

(2015) G. M. Frampton et al.   Cancer Discovery

Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer

(2015) E. L. Kwak et al.   Cancer Discovery

Gastrointestinal malignancies harbor actionable MET exon 14 deletions

(2015) Jeeyun Lee et al.   Oncotarget

Cancer-Associated SF3B1 Hotspot Mutations Induce Cryptic 3′ Splice Site Selection through Use of a Different Branch Point

(2015) Rachel B. Darman et al.   Cell Reports

Blood vessel invasion is a major feature and a factor of poor prognosis in sarcomatoid carcinoma of the lung

(2014) Thibault Vieira et al.   LUNG CANCER

Comprehensive molecular profiling of lung adenocarcinoma

(2014) Eric A. Collisson et al.   NATURE

Acquired resistance to TKIs in solid tumours: learning from lung cancer

(2014) D. Ross Camidge et al.   Nature Reviews Clinical Oncology

Hepatocyte Growth Factor Sensitizes Brain Tumors to c-MET Kinase Inhibition

(2013) Y. Zhang et al.   CLINICAL CANCER RESEARCH

Met/HGF receptor activation is regulated by juxtamembrane Ser985 phosphorylation in hepatocytes

(2013) Mizuho Nakayama et al.   CYTOKINE

Lack of Association of C-Met-N375S Sequence Variant with Lung Cancer Susceptibility and Prognosis

(2013) Jiunn-Min Shieh et al.   International Journal of Medical Sciences

MET and EGFR Mutations Identified in ALK-Rearranged Pulmonary Adenocarcinoma: Molecular Analysis of 25 ALK-Positive Cases

(2013) Jennifer M. Boland et al.   Journal of Thoracic Oncology

Caspase-generated fragment of the Met receptor favors apoptosis via the intrinsic pathway independently of its tyrosine kinase activity

(2013) J Lefebvre et al.   Cell Death & Disease

Hepatocyte Growth Factor, a Determinant of Airspace Homeostasis in the Murine Lung

(2013) Carla Calvi et al.   PLoS Genetics

Phosphoinositide 3-Kinase (PI3K) Pathway Alterations Are Associated with Histologic Subtypes and Are Predictive of Sensitivity to PI3K Inhibitors in Lung Cancer Preclinical Models

(2012) J. M. Spoerke et al.   CLINICAL CANCER RESEARCH

The transcriptional landscape and mutational profile of lung adenocarcinoma

(2012) J.-S. Seo et al.   GENOME RESEARCH

Met Kinase-dependent Loss of the E3 Ligase Cbl in Gastric Cancer

(2012) Andrea Z. Lai et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Phase II and Biomarker Study of the Dual MET/VEGFR2 Inhibitor Foretinib in Patients With Papillary Renal Cell Carcinoma

(2012) Toni K. Choueiri et al.   JOURNAL OF CLINICAL ONCOLOGY

A Novel SND1-BRAF Fusion Confers Resistance to c-Met Inhibitor PF-04217903 in GTL16 Cells though MAPK Activation

(2012) Nathan V. Lee et al.   PLoS One

A Drug Resistance Screen Using a Selective MET Inhibitor Reveals a Spectrum of Mutations That Partially Overlap with Activating Mutations Found in Cancer Patients

(2011) R. Tiedt et al.   CANCER RESEARCH

Multiple Mutations and Bypass Mechanisms Can Contribute to Development of Acquired Resistance to MET Inhibitors

(2011) J. Qi et al.   CANCER RESEARCH

Hepatocyte Growth Factor Expression in EGFR Mutant Lung Cancer with Intrinsic and Acquired Resistance to Tyrosine Kinase Inhibitors in a Japanese Cohort

(2011) Seiji Yano et al.   Journal of Thoracic Oncology

A direct role for Met endocytosis in tumorigenesis

(2011) Carine Joffre et al.   NATURE CELL BIOLOGY

The role of the c-Met pathway in lung cancer and the potential for targeted therapy

(2011) Martin Sattler et al.   Therapeutic Advances in Medical Oncology

Gastric cancer cell line Hs746T harbors a splice site mutation of c-Met causing juxtamembrane domain deletion

(2010) Yoshinari Asaoka et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

MET Receptor Sequence Variants R970C and T992I Lack Transforming Capacity

(2010) J. W. Tyner et al.   CANCER RESEARCH

Acquired Resistance of Non-Small Cell Lung Cancer Cells to MET Kinase Inhibition Is Mediated by a Switch to Epidermal Growth Factor Receptor Dependency

(2010) U. McDermott et al.   CANCER RESEARCH

Cbl and Human Myeloid Neoplasms: The Cbl Oncogene Comes of Age: Figure 1.

(2010) Stephen C. Kales et al.   CANCER RESEARCH

Activation of MET by Gene Amplification or by Splice Mutations Deleting the Juxtamembrane Domain in Primary Resected Lung Cancers

(2010) Ryoichi Onozato et al.   Journal of Thoracic Oncology

CBL Is Frequently Altered in Lung Cancers: Its Relationship to Mutations in MET and EGFR Tyrosine Kinases

(2010) Yi-Hung Carol Tan et al.   PLoS One

Phosphorylation of the MET receptor on juxtamembrane tyrosine residue 1001 inhibits its caspase-dependent cleavage

(2009) Julien Deheuninck et al.   CELLULAR SIGNALLING

Ethnic Differences and Functional Analysis of MET Mutations in Lung Cancer

(2009) S. Krishnaswamy et al.   CLINICAL CANCER RESEARCH